Active Ingredient History
Tick-borne encephalitis vaccine is a vaccine used to prevent tick-borne encephalitis (TBE). The disease is most common in Central and Eastern Europe, and Northern Asia. More than 87% of people who receive the vaccine develop immunity. It is not useful following the bite of an infected tick. It is given by injection into a muscle. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Encephalitis, Tick-Borne (approved 2021)
Allergy and Immunology (Phase 4)
Arthritis, Rheumatoid (Phase 2)
Encephalitis, Tick-Borne (Phase 4)
Flavivirus Infections (Phase 2)
Immune System Diseases (Phase 4)
Immunosuppression Therapy (Phase 2)
Influenza, Human (Phase 3)
Tick-Borne Diseases (Phase 4)
Tuberculosis (Phase 2)
Vaccine Efficacy (Phase 4)
Vaccines (Phase 4)
Virus Diseases (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue